Pf
Non verificato

Pfizer Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute
24/03/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
1.00
23/03/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
1.00
20/03/2026
Scienza
Biotecnologia
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
1.00
19/03/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
1.00
17/03/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
1.00
09/03/2026
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
1.00
27/02/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
1.00
23/02/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
1.00
17/02/2026
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0